After significantly impeding tumor progression in both subcutaneous and intracranial patient-derived xenograft models, an ongoing clinical trial is focusing on the IDH1-R132 mutation, assessing the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor efficacy of DS-1001b [171,172]. The gene discussed is IDH1; the disease is neoplasm.